Background & Objectives: Hypophosphataemic rickets/osteomalacia (HRO) is an uncommon metabolic bone disorder which affects all ages and either sex. It is characterized by low concentration of serum phosphate levels leading to impairment of mineralization of bone matrix with variable aetiology. We present clinical profile and treatment outcome of 17 patients of HRO.
Methods: Seventeen consecutive patients (8 were < 18 yr of age, with median age of presentation being 27.5 yr) of HRO who came to the department of Endocrinology in a tertiary care hospital in north India from January 2000 to December 2006 were included in the present study. Their aetiology, clinical features, biochemical parameters, radiographic features, treatment and outcome were analyzed.
Results: HRO was commoner in females (70.5%) with positive family history observed in 6 (35.3%) patients. Common presenting features were short stature (58.8%), backache (58.8%), bony deformities (58.8%), joint pain (52.9%), fractures (29.4%) and dental abnormalities (23.5%). Radiological abnormalities noted were generalized bony deformities (58.8%), fractures (29.4%), and pseudo fractures (17.6%). Mesenchymal tumours were localized in the pelvis in one patient and in the right jaw in another. The patients were treated with calcium (elemental calcium 1 g/d) and oral phosphate supplements (dose 30 - 50mg/kg/day in divided doses) along with active vitamin D supplements (dose 1 - 3 microg/day) and followed up for a mean of 2 yr. Two patients also received growth hormone (GH) therapy in the dose of 2U/day for 6 and 18 months respectively. Symptomatic well being was reported by all the patients and improvement was noted in the levels of phosphate (P<0.005) and alkaline phosphatase (P<0.05) after treatment.
Interpretation & Conclusions: A diagnosis of HRO should be considered in all patients presenting with short stature, deformities or musculoskeletal pains along with low serum phosphate with normal iPTH and 25--hydroxy vitamin D.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
18F-Sodium Fluoride PET/CT as a Tool to Assess Enthesopathies in X-Linked Hypophosphatemia.
Calcif Tissue Int
January 2025
Endocrinology Department, School of Medicine, Pontificia Universidad Católica de Chile, Av. Diagonal Paraguay 262, Cuarto Piso, Santiago, Chile.
X-linked hypophosphatemia (XLH) is a rare metabolic disorder characterized by elevated FGF23 and chronic hypophosphatemia, leading to impaired skeletal mineralization and enthesopathies that are associated with pain, stiffness, and diminished quality of life. The natural history of enthesopathies in XLH remains poorly defined, partly due to absence of a sensitive quantitative tool for assessment and monitoring. This study investigates the utility of 18F-NaF PET/CT scans in characterizing enthesopathies in XLH subjects.
View Article and Find Full Text PDFNo longer to be ignored: Hypophosphatemia following intravenous iron administration.
Rev Endocr Metab Disord
December 2024
Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium.
Intravenous iron supplementation is increasingly used to safely and effectively correct iron deficiency anemia, but some formulations are linked to a renal phosphate wasting syndrome which is mediated by fibroblast growth factor 23. Unawareness among prescribers and the nonspecific clinical symptoms of hypophosphatemia result in underreporting of this complication. Even though it is often an asymptomatic and self-limiting condition, accumulating evidence from case reports and dedicated randomized controlled trials show that IV iron induced hypophosphatemia may be associated with clinical symptoms.
View Article and Find Full Text PDFImpact of X-linked hypophosphatemic rickets/osteomalacia on health and quality of life: baseline data from the SUNFLOWER longitudinal, observational cohort study.
JBMR Plus
November 2024
Center for Promoting Treatment of Intractable Diseases, ISEIKAI International General Hospital, Osaka 530-0052, Japan.
Article Synopsis
- * The research included data from 147 patients (77 children and 70 adults) who were mostly treated with phosphate and active vitamin D, revealing significant challenges related to height, pain severity, and quality of life (QOL) in both age groups.
- * Findings showed that while children reported low pain levels, adults experienced mild-to-moderate pain, with both groups experiencing low QOL, which highlights the ongoing need for better understanding and management strategies for XL
Autosomal recessive hypophosphatemic rickets type 2 due to ENPP1 deficiency (ARHR2).
Arch Pediatr
September 2024
AP-HP, Paris Saclay University, INSERM; Centre de Référence des Maladies Rares du Calcium et du Phosphore, Service d'Endocrinologie et diabète de l'enfant, Filières Santé Maladies Rares OSCAR, ERN endoRARE et BOND, Hôpital Bicêtre Paris-Saclay; U1185 physiologie et physiopathologie endocrinienne; Le Kremlin Bicêtre, France.
Article Synopsis
- - Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) is a rare disorder linked to mutations in the ENPP1 gene, leading to a variety of health issues, including GACI, OPLL, and pseudoxanthoma elasticum.
- - ARHR2 manifests with elevated serum FGF23 levels, causing phosphate loss in the kidneys, resulting in symptoms similar to other hypophosphatemic rickets, including rickets in children and osteomalacia in adults.
- - Genetic testing is crucial for diagnosing ARHR2 to ensure patients receive appropriate treatment options and access to clinical trials for new therapies.
Alteration of bone microarchitecture in hereditary distal RTA patients with SLC4A1 gene mutation: assessed by HR-pQCT.
J Clin Endocrinol Metab
August 2024
Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Article Synopsis
- - SLC4A1-dRTA is a rare genetic form of renal tubular acidosis that often leads to bone issues like rickets or osteomalacia, impacting patients' daily lives.
- - A study evaluated the bone microstructure of 11 SLC4A1-dRTA patients and found significant skeletal problems, including lower bone density and more severe bone deterioration compared to healthy individuals and patients with X-linked hypophosphatemic rickets (XLH).
- - The research highlighted the common occurrence of skeletal symptoms in SLC4A1-dRTA and emphasized the importance of early diagnosis and treatment, as patients showed improvement in bone pain and height with long-term alkaline therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!